SBRT in the Very Elderly: A Viable Option for Pulmonary Oligometastases?
Cancers · 30.07.2025 · 17 (15) · 2512
DOI: 10.3390/cancers17152512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.07.2025. Verfasst von Samuel M Vorbach und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The global population of individuals aged ≥ 80 years is rapidly growing, leading to an increasing incidence of cancer diagnoses in this age group. While stereotactic body radiotherapy (SBRT) has proven effective in treating pulmonary oligometastases, patients over 80 remain underrepresented in clinical analyses. This study aimed to evaluate clinical outcomes and toxicity of SBRT for pulmonary oligometastases in octogenarians.
Methods
This retrospective, single-centre analysis included 34 patients aged ≥ 80 years treated with SBRT for histologically confirmed pulmonary oligometastases between 2010 and 2024.
Results
A total of 46 pulmonary metastases were treated with curative intent using fractionation schemes of 3 × 15 Gy, 6 × 8 Gy, or 10 × 6 Gy. Median biologically effective dose (BED10) was 112.5 Gy. Follow-up included regular CT imaging and toxicity assessment according to CTCAE. With a median follow-up of 22.6 months, 1-, 2-, and 3-year local control (LC) rates were 95.2%, 95.2%, and 90.2%, respectively. Median overall survival (OS) was 46.6 months, with 1-, 2-, and 3-year OS rates of 78.4%, 71.4%, and 59.5%. Progression-free survival (PFS) at 1, 2, and 3 years was 63.4%, 51.6%, and 47.3%, respectively. No grade ≥ 3 toxicities were observed. Grade 2 pneumonitis and dermatitis occurred in 2.9% each and were well managed. Asymptomatic rib fractures were detected in 5.9% of patients. No significant predictors for LC, PFS, or OS were identified in univariate analysis.
Conclusions
SBRT for pulmonary oligometastases in patients ≥ 80 years is feasible, safe, and effective. High local control, favourable cancer-specific survival, and minimal toxicity support its use as a curative-intent treatment in this growing patient population. These findings contribute important site- and age-specific evidence and support the inclusion of very elderly patients in future prospective SBRT trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Samuel M Vorbach, Thomas Seppi
Zitieren
APA
Vorbach, S. M., Nevinny-Stickel, M., Ganswindt, U., & Seppi, T. (2025). SBRT in the Very Elderly: A Viable Option for Pulmonary Oligometastases?. Cancers, 17(15), 2512. https://doi.org/10.3390/cancers17152512
Vancouver
Vorbach SM, Nevinny-Stickel M, Ganswindt U, Seppi T. SBRT in the Very Elderly: A Viable Option for Pulmonary Oligometastases?. Cancers. 2025;17(15):2512. doi:10.3390/cancers17152512
BibTeX
@article{Vorbach2025,
author = {Vorbach, Samuel M and Nevinny-Stickel, Meinhard and Ganswindt, Ute and Seppi, Thomas},
title = {SBRT in the Very Elderly: A Viable Option for Pulmonary Oligometastases?},
journal = {Cancers},
year = {2025},
volume = {17},
number = {15},
pages = {2512},
doi = {10.3390/cancers17152512}
}
EUVIMED